Defective STING signaling in low-grade serous ovarian cancer: an opportunity for oncolytic viruses therapy

被引：0
|
作者：
Zhantuyakova, Almira
Cochrane, Dawn
Negri, Gian Luca
Miko, Sandra Spencer
Azad, Taha
Fernandez, Marta Llaurado
Carey, Mark
Morin, Gregg B.
Bell, John
Huntsman, David D.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-B054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B054
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Stage I low-grade serous ovarian cancer: Is there a benefit to chemotherapy?
    Vue, Nujsaubnusi
    Horne, Zachary
    Crafton, Sarah
    Krivak, Thomas
    Miller, Eirwen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S286 - S286
  • [32] Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
    Karacin, Cengiz
    Sunar, Veli
    Urakci, Zuhat
    Yilmaz, Ali
    Ayhan, Murat
    Ersoy, Mustafa
    Guven, Deniz Can
    Erturk, Ismail
    Durmus, Yasin
    Karacin, Pinar
    Boran, Nurettin
    Ustun, Yaprak Engin
    Meydan, Mutlu
    Dogan, Mutlu
    Oksuzoglu, Berna
    Ates, Ozturk
    Karaca, Mustafa
    Uncu, Dogan
    Ergun, Yakup
    Arik, Zafer
    FUTURE ONCOLOGY, 2024, 20 (04) : 207 - 214
  • [33] New therapeutic opportunities for women with low-grade serous ovarian cancer
    Moujaber, Tania
    Balleine, Rosemary L.
    Gao, Bo
    Madsen, Ida
    Harnett, Paul R.
    DeFazio, Anna
    ENDOCRINE-RELATED CANCER, 2022, 29 (01) : R1 - R16
  • [34] Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?
    Vineyard, Marisa A.
    Daniels, Molly S.
    Urbauer, Diana L.
    Deavers, Michael T.
    Sun, Charlotte C.
    Boerwinkle, Eric
    Bodurka, Diane C.
    Gershenson, David M.
    Crawford, Jessica
    Lu, Karen H.
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 229 - 232
  • [35] Is low-grade serous ovarian cancer part of the hereditary breast and ovarian cancer tumor spectrum?
    Daniels, M.
    Vineyard, M.
    Urbauer, D.
    Deavers, M.
    Sun, C.
    Boerwinkle, E.
    Bodurka, D.
    Gershenson, D.
    Lu, K.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S98 - S99
  • [36] Characterizing the genomic and immunologic landscape of serous borderline tumors and low-grade serous ovarian cancer
    Krishnan, Rahul
    Bilecz, Agnes
    Herbst, Paula
    Shimizu, Aasa
    Schweizer, Lisa
    Jaeger, Ellen
    Godden, Jen
    Stoppler, Melissa
    Yamada, Diane
    Lengyel, Ernst
    CANCER RESEARCH, 2024, 84 (05)
  • [37] Cost-effectiveness of maintenance hormonal therapy in patients with advanced low-grade serous ovarian cancer
    Nica, A. I.
    Lee, J. J. Y.
    Hong, N. Look
    May, T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 107 - 107
  • [38] Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum
    Hinson, Stacy A.
    Silva, Elvio G.
    Pinto, K.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2013, 17 (03) : 302 - 304
  • [39] Targeted Therapies in Low-Grade Serous Ovarian Cancers
    Gonzalez, Anna
    Nagel, Christa I.
    Haight, Paulina J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (07) : 854 - 868
  • [40] The tuba origin of low-grade serous ovarian carcinoma
    Kong, Beihua
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S74 - S74
12345